Coenzyme Q10 and Fatty Liver: Evidence & Safety

Coenzyme Q10 and fatty liver disease are increasingly discussed together as interest grows in antioxidant approaches to liver health. Fatty liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), affects a significant proportion of UK adults and is closely linked to insulin resistance, obesity, and type 2 diabetes. Coenzyme Q10 (CoQ10) is a naturally occurring compound central to mitochondrial energy production and antioxidant defence, both of which are impaired in fatty liver disease. This article explores the science behind CoQ10, what the clinical evidence shows, and what UK patients should know before considering supplementation.

What is fatty liver disease and why does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, most commonly due to insulin resistance, obesity, or type 2 diabetes. Oxidative stress and mitochondrial dysfunction drive progression from simple steatosis to more severe liver injury.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, impairing normal hepatic function over time. It is broadly divided into two main categories: metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD). MASLD was previously known as non-alcoholic fatty liver disease (NAFLD), and NHS and NICE publications may still use the NAFLD terminology; both terms refer to the same condition. The MASLD/MASH nomenclature reflects an international consensus update (EASL, 2023) and is increasingly used in UK clinical practice, though NICE NG49 was published before this renaming and retains the NAFLD/NASH terminology.^[1]

MASLD develops when the liver's capacity to process and export fat is overwhelmed, typically in the context of insulin resistance, obesity, type 2 diabetes, or dyslipidaemia. Excess dietary calories, particularly from refined carbohydrates and saturated fats, promote triglyceride accumulation within hepatocytes. Over time, this can progress through a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.

Oxidative stress plays a central role in this progression. When fat accumulates in the liver, it generates reactive oxygen species (ROS) that damage cell membranes, proteins, and DNA. Mitochondrial dysfunction is closely linked to this process, as the liver's energy-producing organelles become less efficient under conditions of chronic lipid overload. This is particularly relevant when considering the potential role of antioxidant compounds such as coenzyme Q10.

NICE guidance (NG49) recommends lifestyle modification, including dietary change and increased physical activity, as the cornerstone of MASLD/NAFLD management. In UK primary care, risk stratification typically involves non-invasive scoring tools such as the Fibrosis-4 (FIB-4) index or the NAFLD Fibrosis Score (NFS) to identify people who may need further assessment, for example with the Enhanced Liver Fibrosis (ELF) test or specialist referral, in line with NICE NG49 recommendations. There is currently no licensed pharmacological treatment specifically approved for MASLD in the UK at the time of writing; anyone with concerns about their diagnosis or management should speak with their GP.^[3][4]

How does coenzyme Q10 affect the liver?

CoQ10 supports mitochondrial energy production and acts as a lipid-phase antioxidant in hepatocytes, potentially reducing oxidative stress and inflammatory signalling. These mechanisms are established mainly in laboratory and animal studies, with limited human evidence.

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble compound produced naturally by the body that plays an essential role in mitochondrial energy production and acts as a potent antioxidant. Within the liver, CoQ10 is concentrated in the inner mitochondrial membrane, where it facilitates the electron transport chain, enabling hepatocytes to generate adenosine triphosphate (ATP) efficiently.^[16]

It is important to state at the outset that the mechanisms described below have been demonstrated primarily in laboratory and animal studies. The translation of these findings to human liver disease requires careful evaluation through well-designed clinical trials, and the evidence base in humans remains limited and evolving.

In the context of fatty liver disease, CoQ10 is thought to be relevant for several reasons. Mitochondrial dysfunction is a recognised feature of MASLD, and CoQ10 is integral to mitochondrial respiratory function. Reduced hepatic CoQ10 levels have been observed in animal models of fatty liver, suggesting that depletion may contribute to impaired energy metabolism and increased oxidative damage.^[5] CoQ10 also acts as a lipid-phase antioxidant, neutralising ROS before they can damage hepatocyte membranes and trigger inflammatory cascades. By reducing oxidative stress, CoQ10 may theoretically interrupt the progression from simple steatosis to steatohepatitis, which is characterised by hepatocyte ballooning, lobular inflammation, and fibrosis.

Some preclinical evidence suggests CoQ10 may modulate inflammatory signalling pathways, including the suppression of nuclear factor kappa B (NF-kB), a key driver of hepatic inflammation.^[6][7] It may also support fatty acid beta-oxidation within mitochondria, potentially reducing hepatic lipid accumulation. These are plausible mechanisms, but they remain to be confirmed in robust human trials.

Can CoQ10 supplements actually help with fatty liver?

Small RCTs suggest CoQ10 may modestly reduce liver enzyme levels and inflammatory markers in MASLD, but evidence is insufficient for routine clinical recommendation. CoQ10 is not a licensed treatment in the UK and does not replace lifestyle modification.

The available clinical evidence suggests that CoQ10 supplementation may offer modest benefits in people with MASLD, though the evidence base is not yet sufficient to support routine clinical recommendation.

Several small randomised controlled trials have examined CoQ10 in patients with MASLD. A randomised trial by Farsi et al. (Nutrition, 2016) found that CoQ10 supplementation over 12 weeks was associated with significant reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both markers of liver cell injury, compared with placebo. Participants also showed improvements in fasting blood glucose and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP). The trial was small, however, and the findings require replication in larger, longer-duration studies.

Subsequent research, including further small RCTs and emerging systematic reviews, has broadly reported similar signals: modest improvements in liver enzyme levels and markers of oxidative stress, with some studies also noting improvements in metabolic parameters. However, the overall body of evidence is limited by small sample sizes, short follow-up periods, heterogeneity in doses and outcome measures, and a lack of histological endpoints. Importantly, histological improvement or fibrosis regression has not been demonstrated in human trials of CoQ10, and imaging-based assessments of hepatic steatosis have produced inconsistent results across studies.^[17][8]

Some research has explored CoQ10 in combination with lifestyle interventions, with some evidence suggesting an additive benefit on hepatic steatosis assessed by ultrasound, though it is difficult to isolate the contribution of CoQ10 from concurrent dietary changes.

CoQ10 is not a licensed treatment for MASLD in the UK, and NICE does not currently recommend it as part of standard care. Lifestyle modification and weight management remain the cornerstone of treatment per NICE NG49, and supplements should not replace these. Anyone considering supplementation should discuss this with their GP, particularly if they are taking other medications or have underlying health conditions. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online health consultations, with prescriber review and pharmacist support, where questions about supplement use alongside medical management can be explored.

What does the evidence say about CoQ10 dosage and safety?

Clinical trials have used 100 mg to 300 mg of CoQ10 daily, taken with food; it is generally well tolerated with mild gastrointestinal side effects. CoQ10 may interact with warfarin, so GP advice is essential before starting supplementation.

CoQ10 is generally considered well tolerated in adults, with a favourable safety profile observed across a range of doses used in clinical research. In studies examining its use in MASLD, doses have typically ranged from 100 mg to 300 mg per day, taken orally with food to enhance absorption, as CoQ10 is fat-soluble and bioavailability improves when consumed alongside dietary fat.^[8][9] These dosing figures are drawn from the clinical trial literature, including the Farsi et al. (2016) trial and related RCTs; they do not represent a licensed or officially recommended dose.

Common adverse effects reported in trials are mild and infrequent, and may include:

• Gastrointestinal symptoms such as nausea, diarrhoea, or stomach discomfort

• Headache or dizziness, particularly at higher doses

Some sources anecdotally report difficulty sleeping when CoQ10 is taken late in the day, though this has not been consistently demonstrated in clinical trials; if this is a concern, taking the supplement earlier in the day is a reasonable precaution.

CoQ10 may interact with certain medications. It has a structural similarity to vitamin K and may theoretically reduce the anticoagulant effect of warfarin.^[10][11] Anyone taking warfarin should inform their GP or anticoagulation clinic before starting CoQ10, and INR monitoring may be appropriate. There is also some suggestion of potential interactions with certain antihypertensive and chemotherapy agents, though the evidence for these is limited and largely theoretical; anyone taking these medicines should seek advice from their GP, pharmacist, or specialist before using CoQ10.

CoQ10 is available as a food supplement in the UK without prescription. Food supplements are not subject to the same regulatory standards as licensed medicines, and the quality and concentration of commercially available products can vary considerably.^[13] For guidance on food supplement regulation in the UK, the Food Standards Agency (FSA) publishes relevant information at food.gov.uk.

People with advanced liver disease should discuss any supplement use with their hepatology team before starting. Pregnant or breastfeeding women should avoid CoQ10 supplementation unless specifically advised by a healthcare professional, as safety data in these populations is insufficient. Anyone experiencing unexplained worsening of symptoms, jaundice, or significant abdominal pain should contact their GP promptly rather than self-managing with supplements. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.^[14][15]mhra.gov.uk.

Scientific References

1. MASLD nomenclature international consensus update (EASL et al.).
2. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline NG49.
3. NICE GID-TA11477 draft scope post-referral: treatment of MASLD — no medicines currently approved in the UK.
4. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
5. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. Chen K et al..
6. CoQ10 attenuated neuroinflammatory responses through inactivation of NF-κB dependent inflammatory pathways. Li L et al..
7. Coenzyme Q10 attenuates inflammation and fibrosis implicated in radiation enteropathy through suppression of NF-kB/TGF-β/MMP-9 pathways. Mohamed HA et al..
8. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Farsi F et al. Nutrition 2016..
9. Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with MASLD: a randomized double-blind, placebo-controlled trial. Cardiovascular Diabetology 2024..
10. Interaction between warfarin and coenzyme Q10. Landbo C, Almdal TP. Ugeskr Laeger 1998..
11. Risk of warfarin-related bleeding events and supratherapeutic INRs associated with complementary and alternative medicine. Shalansky S et al. Pharmacotherapy 2007..
12. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. Engelsen J et al. Thrombosis and Haemostasis 2002..
13. Nutrition legislation information sheet — food supplements regulation in the UK.
14. Yellow Card scheme — reporting suspected adverse reactions to medicines and supplements.
15. Adverse reactions to drugs — Yellow Card scheme. BNF/NICE..
16. Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1 (NQO1). Free Radical Research 2002..
17. Effects of coenzyme Q10 supplementation on lipid profiles and liver enzymes of NAFLD patients: a systematic review and meta-analysis of RCTs. Zamani M et al. Food Science & Nutrition 2023..

Frequently Asked Questions